Joint Clinical Trials Office

You are here

Radiotherapy and Immunotherapy for Systemic Effect in Myeloma (RISE-M) Trial

Clinical Trial Details

Combining radiotherapy with immunotherapy (treatment that boosts your immune system to fight cancer), presents potential therapeutic advantages. Because of its localized nature, radiotherapy is devoid of most systemic effects, including interference with systemic immunotherapy, commonly encountered with chemotherapy. 

The purpose of this study is to estimate overall response rate in patients with multiple myeloma when treated with a combination of local radiotherapy and nivolumab (immunotherapy). In addition, the investigators are interested in evaluating progression free survival and overall survival in patients treated with the combination of radiation and immunotherapy. 

Key Eligibility: 
  • Must have received 2 consecutive cycles of systemic myeloma therapy 
  • Documented refractory or relapsed and refractory (R/R) multiple myeloma 
  • Targetable plasmacytoma, either intra-or extramedullary that is visualized on imaging (PET/CT or MRI) and is causing symptoms (eg. pain, neurological compromise) or potential to cause symptom as per clinician’s judgement; and measurable disease at screening  
  • Males and Females at least 18 years or legal age of consent per local regulations 

Study contact by location

Upper East Side - Manhattan


Kathleen Pogonowski, RN

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group